[Treatment of the neuroleptic syndrome by biperiden hydrochloride under its delayed-action form. A 9-month study on 55 hospitalized patients].
Biperiden hydrochloride has been used in the treatment of Parkinson's disease and related disorders within two drugs: --Akinophyl, --and Akineton which is chemically similar but has a slower effect. The first French publications upon its use as a neuroleptic corrector date from 1972. Our study deals with 55 chronic psychotic patients treated with neuroleptics and varied correctors of resulting Parkinson disorders. Akineton has been substituted for the preceding antiparkinson drugs. We may come to the following conclusions = Akineton is effective upon neuroleptic syndrom, gives few or no untoward reactions, has no toxicologic effects, shows no incompatibility with any other drug. It is very satisfactory to have at our disposal a drug effective in small doses and having a slow effect within average of 24 hours.
D000328:Adult; D000368:Aged; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy*; D001712:Biperiden / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D010880:Piperidines; D001712:Biperiden
Traitement du syndrome neuroleptique par le chlorhydrate de bipéridène sous sa forme retard. Etude sur 9 mois de 55 malades hospitalisés